Concord Biotech Limited Stock

Equities

CONCORDBIO

INE338H01029

Pharmaceuticals

Delayed NSE India S.E. 07:43:53 2024-06-24 EDT 5-day change 1st Jan Change
1,522 INR -2.41% Intraday chart for Concord Biotech Limited -3.84% +3.41%

Financials

Sales 2025 * 12.45B 149M 204M Sales 2026 * 15.19B 182M 249M Capitalization 163B 1.96B 2.68B
Net income 2025 * 3.91B 46.89M 64.15M Net income 2026 * 5B 59.95M 82.02M EV / Sales 2025 * 12.9 x
Net cash position 2025 * 2.68B 32.17M 44.01M Net cash position 2026 * 3.96B 47.51M 65.01M EV / Sales 2026 * 10.5 x
P/E ratio 2025 *
41.7 x
P/E ratio 2026 *
32.7 x
Employees 1,377
Yield 2025 *
0.63%
Yield 2026 *
0.8%
Free-Float 24.61%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.41%
1 week-3.84%
Current month+4.00%
1 month+4.85%
3 months+1.65%
6 months+1.06%
Current year+3.41%
More quotes
1 week
1 516.00
Extreme 1516
1 595.40
1 month
1 327.05
Extreme 1327.05
1 595.40
Current year
1 327.05
Extreme 1327.05
1 725.00
1 year
900.05
Extreme 900.05
1 725.00
3 years
900.05
Extreme 900.05
1 725.00
5 years
900.05
Extreme 900.05
1 725.00
10 years
900.05
Extreme 900.05
1 725.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 42 09-12-03
Chief Executive Officer 71 00-05-09
Director of Finance/CFO 58 22-03-13
Members of the board TitleAgeSince
Director/Board Member 64 22-05-23
Director/Board Member 79 17-01-30
Director/Board Member 56 17-01-30
More insiders
Date Price Change Volume
24-06-24 1,522 -2.41% 31 956
24-06-21 1,560 -0.77% 78,790
24-06-20 1,572 -0.26% 54,011
24-06-19 1,576 -0.43% 43,629
24-06-18 1,583 +3.41% 97,548

Delayed Quote NSE India S.E., June 24, 2024 at 07:43 am

More quotes
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. It manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. It also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The Company provides products in the critical care, immunology, nephrology, and transplant medicine segments.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,560 INR
Average target price
1,622 INR
Spread / Average Target
+3.97%
Consensus
  1. Stock Market
  2. Equities
  3. CONCORDBIO Stock